浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Nephrotoxicity caused by polymyxin in the treatment of drug-resistant Gram-negative bacterial infections：a meta-analysis
- ZHONGGUO YAOFANG Vol. 34, Issue 22, Pages: 2793-2799(2023)
- 作者机构：
1.内蒙古科技大学包头医学院第一附属医院药物临床研究室，内蒙古 包头 014010
2.包头市第八医院药剂科，内蒙古 包头 014040
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2023.22.19
CLC： R978.1+6Published：30 November 2023，
Received：27 April 2023，
Revised：25 October 2023，
扫 描 看 全 文
王晓洁,董志强,董媛等.多黏菌素治疗耐药革兰氏阴性菌感染致肾毒性的Meta分析 Δ[J].中国药房,2023,34(22):2793-2799.
WANG Xiaojie,DONG Zhiqiang,DONG Yuan,et al.Nephrotoxicity caused by polymyxin in the treatment of drug-resistant Gram-negative bacterial infections：a meta-analysis[J].ZHONGGUO YAOFANG,2023,34(22):2793-2799.
王晓洁,董志强,董媛等.多黏菌素治疗耐药革兰氏阴性菌感染致肾毒性的Meta分析 Δ[J].中国药房,2023,34(22):2793-2799. DOI： 10.6039/j.issn.1001-0408.2023.22.19.
WANG Xiaojie,DONG Zhiqiang,DONG Yuan,et al.Nephrotoxicity caused by polymyxin in the treatment of drug-resistant Gram-negative bacterial infections：a meta-analysis[J].ZHONGGUO YAOFANG,2023,34(22):2793-2799. DOI： 10.6039/j.issn.1001-0408.2023.22.19.
摘要
目的
2
评价耐药革兰氏阴性菌感染患者使用多黏菌素后的肾毒性发生情况，为临床用药提供循证参考。
方法
2
计算机检索PubMed、Embase、Web of Science、the Cochrane Library、万方数据、中国知网、维普网和中国生物医学数据库，收集多黏菌素（试验组）对比其他抗菌药物（对照组）或者多黏菌素B（试验组）对比多黏菌素E（对照组）的随机对照试验（RCT）或队列研究，筛选文献、提取数据和质量评价后，采用RevMan 5.4.1软件进行Meta分析。
结果
2
共纳入37项研究，其中4篇RCT、33篇队列研究，共计5 871例患者。Meta分析结果显示，RCT[RR＝2.64，95%CI（1.43，4.87），
P
＝0.002]和队列研究[RR＝1.59，95%CI（1.27，1.98），
P
＜0.000 1]中，试验组患者的肾毒性发生率均显著高于对照组。队列研究亚组分析结果显示，试验组中使用多黏菌素患者的肾毒性发生率显著高于对照组中使用新型
β
-内酰胺及其酶抑制剂类药物、替加环素的患者；使用改善全球肾脏病预后组织指南标准、肾脏替代治疗标准、血肌酐升高0.5倍标准时，试验组患者的肾毒性发生率亦显著高于对照组（
P
＜0.05）。使用多黏菌素E患者的肾毒性发生率显著高于使用多黏菌素B患者[RR＝0.57，95%CI（0.39，0.84），
P
＝0.005]。
结论
2
在耐药革兰氏阴性菌感染的治疗中，多黏菌素的肾毒性发生率较高，且多黏菌素E高于多黏菌素B。
Abstract
OBJECTIVE
2
To evaluate the incidence of nephrotoxicity in patients with drug-resistant Gram-negative bacterial infections after the use of polymyxin， and to provide evidence-based reference for clinical rational drug use.
METHODS
2
PubMed， Embase， Web of Science， the Cochrane Library， Wanfang database， CNKI， VIP and SinoMed were searched to collect randomized controlled trials （RCTs） or cohort studies about the polymyxin （trial group） versus other antibiotics （control group） or polymyxin B （trial group） versus polymyxin E （control group）. After literature screening， data extraction and quality evaluation， RevMan 5.4.1 software was used for meta-analysis.
RESULTS
2
A total of 37 studies were included， including 4 RCTs and 33 cohort studies， with a total of 5 871 patients. The meta-analysis results showed that in RCT [RR＝2.64，95%CI （1.43，4.87），
P
＝0.002] and in cohort studies [RR＝1.59， 95%CI （1.27， 1.98），
P
＜0.000 1]， the incidence of nephrotoxicity in the trial group was significantly higher than control group. The results of the subgroup analysis of cohort studies showed that the incidence of nephrotoxicity in the trial group （receiving polymyxin） was significantly higher than
control group （receiving new
β
-lactam and
β
-lactamase inhibitors and tigecycline）； when Kidney Disease Improving Global Outcomes （KDIGO）， renal replacement therapy or 0.5 times increase in serum creatinine were used as the standard of nephrotoxicity， the incidence of nephrotoxicity in the trial group was significantly higher than the control group （
P
＜0.05）. The incidence of nephrotoxicity in patients receiving polymyxin E was significantly higher than those using polymyxin B [RR＝0.57， 95%CI （0.39，0.84），
P
＝0.005].
CONCLUSIONS
2
In the treatment of drug-resistant Gram-negative bacteria infections， the incidence of nephrotoxicity caused by polymyxin is relatively high. The incidence of nephrotoxicity caused by polymyxin E is higher than polymyxin B.
关键词
多黏菌素肾毒性耐药革兰氏阴性菌感染
Keywords
nephrotoxicitydrug-resistant Gram- negative bacteriainfection
references
NORDMANN P，POIREL L. Epidemiology and diag-nostics of carbapenem resistance in Gram-negative bacteria[J]. Clin Infect Dis，2019，69（Suppl 7）：S521-S528.
SANGTHAWAN P，GEATER A F，NAORUNGROJ S，et al. Characteristics，influencing factors，predictive scoring system，and outcomes of the patients with nephrotoxicity associated with administration of intravenous colistin[J]. Antibiotics，2021，11（1）：2.
ALOTAIBI F M，ALSHEHAIL B M，AL JAMEA Z A H，et al. Incidence and risk factors of colistin-induced nephrotoxicity associated with the international consensus guidelines for the optimal use of the polymyxins：a retrospective study in a tertiary care hospital，Saudi Arabia[J]. Antibiotics，2022，11（11）：1569.
刘昌伟，胡立芬，汪燕燕，等. 多黏菌素B治疗耐碳青霉烯革兰阴性菌脓毒症的疗效和肾毒性[J]. 上海医药，2022，43（13）：26-28，50.
LIU C W，HU L F，WANG Y Y，et al. Effectiveness and nephrotoxicity of polymyxin B in the treatment of sepsis caused by carbapenem-resistant Gram-negative bacteria[J]. Shanghai Med Pharm J，2022，43（13）：26-28，50.
HIGGINS J P T，ALTMAN D G，GØTZSCHE P C，et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials[J]. BMJ，2011，343：d5928.
STANG A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysis[J]. Eur J Epidemiol，2010，25（9）：603-605.
MOGYORÓDI B，CSÉKÓ A B，HERMANN C，et al. Ceftolozane/tazobactam versus colistin in the treatment of ventilator-associated pneumonia due to extensively drug-resistant Pseudomonas aeruginosa[J]. Sci Rep，2022，12（1）：4455.
DOREMUS C，MARCELLA S W，CAI B，et al. Utilization of colistin versus β-lactam and β-lactamase inhibitor agents in relation to acute kidney injury in patients with severe Gram-negative infections[J]. Infect Dis Ther，2022，11（1）：187-199.
CHANG K，WANG H B，ZHAO J P，et al. Polymyxin B/tigecycline combination vs. polymyxin B or tigecycline alone for the treatment of hospital-acquired pneumonia caused by carbapenem-resistant Enterobacteriaceae or carbapenem-resistant Acinetobacter baumannii[J]. Front Med，2022，9：772372.
ALMANGOUR T A，ALJABRI A，MUSAWA M A，et al. Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa：a multicentre cohort study[J]. J Glob Antimicrob Resist，2022，28：288-294.
ALMANGOUR T A，GHONEM L，ALJABRI A，et al. Ceftazidime-avibactam versus colistin for the treatment of infections due to carbapenem-resistant enterobacterales：a multicenter cohort study[J]. Infect Drug Resist，2022，15：211-221.
HEYBELI C，CANASLAN K，OKTAN M A，et al. Acute kidney injury following colistin treatment in critically-ill patients：may glucocorticoids protect?[J]. J Chemother，2021，33（2）：85-94.
BABAR Z U，DODANI S K，NASIM A. Treatment outcome and adverse effects of colistin in adult patients with carbapenem-resistant Gram-negative bacteremia from Pakistan[J]. Int J Infect Dis，2021，106：171-175.
BROWN M L，MOTSCH J，KAYE K S，et al. Evaluation of renal safety between imipenem/relebactam and colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections in the randomized，phase 3 RESTORE-IMI 1 study[J]. Open Forum Infect Dis，2020，7（3）：ofaa054.
POURHEIDAR E，HAGHIGHI M，KOUCHEK M，et al. Comparison of intravenous ampicillin-sulbactam plus nebulized colistin with intravenous colistin plus nebulized colistin in treatment of ventilator associated pneumonia caused by multi drug resistant Acinetobacter baumannii：randomized open label trial[J]. Iran J Pharm Res，2019，18（Suppl1）：269-281.
MIANO T A，LAUTENBACH E，WILSON F P，et al. Attributable risk and time course of colistin-associated acute kidney injury[J]. Clin J Am Soc Nephrol，2018，13（4）：542-550.
KHALILI H，SHOJAEI L，MOHAMMADI M，et al. Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia[J]. J Comp Eff Res，2018，7（9）：901-911.
ZALTS R，NEUBERGER A，HUSSEIN K，et al. Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia：retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam[J]. Am J Ther，2016，23（1）：e78-e85.
ROCCO M，MONTINI L，ALESSANDRI E，et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics：a retrospective cohort study[J]. Crit Care，2013，17（4）：R174.
OLIVEIRA M S，PRADO G V，COSTA S F，et al. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp[J]. J Antimicrob Chemother，2008，61（6）：1369-1375.
İPEK M S，AKTAR F，OKUR N，et al. Colistin use in critically ill neonates：a case-control study[J]. Pediatr Neonatol，2017，58（6）：490-496.
BETROSIAN A P，FRANTZESKAKI F，XANTHAKI A，et al. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia[J]. J Infect，2008，56（6）：432-436.
CHUANG Y C，CHENG C Y，SHENG W H，et al. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting：a matched cohort analysis[J]. BMC Infect Dis，2014，14：102.
DURAKOVIC N，RADOJCIC V，BOBAN，et al. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy：a matched pair analysis[J]. Intern Med，2011，50（9）：1009-1013.
GARNACHO-MONTERO J，ORTIZ-LEYBA C，JIMÉNEZ-JIMÉNEZ F J，et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia（VAP）with intravenous colistin：a comparison with imipenem-susceptible VAP[J]. Clin Infect Dis，2003，36（9）：1111-1118.
GOUNDEN R，BAMFORD C，VAN ZYL-SMIT R，et al. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections[J]. BMC Infect Dis，2009，9：26.
HACHEM R Y，CHEMALY R F，AHMAR C A，et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients[J]. Antimicrob Agents Chemother，2007，51（6）：1905-1911.
KALLEL H，HERGAFI L，BAHLOUL M，et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia：a matched case-control study[J]. Intensive Care Med，2007，33（7）：1162-1167.
KARABAY O，BATIREL A，BALKAN I，et al. Efficacy of colistin and non-colistin monotherapies in multi-drug resistant Acinetobacter baumannii bacteremia/sepsis[J]. Acta Medica Mediterranea，2014，30：1137-1143.
KIM W Y，MOON J Y，HUH J W，et al. Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients[J]. PLoS One，2016，11（3）：e0150642.
KOOMANACHAI P，TIENGRIM S，KIRATISIN P，et al. Efficacy and safety of colistin（colistimethate sodium）for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital，Bangkok，Thailand[J]. Int J Infect Dis，2007，11（5）：402-406.
KWON S H，AHN H L，HAN O Y，et al. Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii[J]. Biol Pharm Bull，2014，37（3）：340-346.
LIM S K，LEE S O，CHOI S H，et al. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections[J]. J Korean Med Sci，2011，26（3）：325-331.
PAUL M，BISHARA J，LEVCOVICH A，et al. Effectiveness and safety of colistin：prospective comparative cohort study[J]. J Antimicrob Chemother，2010，65（5）：1019-1027.
REINA R，ESTENSSORO E，SÁENZ G，et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections：a prospective cohort study[J]. Intensive Care Med，2005，31（8）：1058-1065.
RIOS F G，LUNA C M，MASKIN B，et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms[J]. Eur Respir J，2007，30（2）：307-313.
SHIELDS R K，NGUYEN M H，CHEN L，et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia[J]. Antimicrob Agents Chemother，2017，61（8）：e00883-e00817.
AGGARWAL R，DEWAN. Comparison of nephrotoxicity of colistin with polymyxin B administered in currently recommended doses：a prospective study[J]. Ann Clin Microbiol Antimicrob，2018，17（1）：15.
CRASS R L，RUTTER W C，BURGESS D R，et al. Nephro-toxicity in patients with or without cystic fibrosis treated with polymyxin B compared to colistin[J]. Antimicrob Agents Chemother，2017，61（4）：e02329-e02316.
RIGATTO M H，OLIVEIRA M S，PERDIGÃO-NETO L V，et al. Multicenter prospective cohort study of renal fai-lure in patients treated with colistin versus polymyxin B[J]. Antimicrob Agents Chemother，2016，60（4）：2443-2449.
PHE K，LEE Y M，MCDANELD P M，et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy[J]. Antimicrob Agents Chemother，2014，58（5）：2740-2746.
TUON F F，RIGATTO M H，LOPES C K，et al. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium[J]. Int J Antimicrob Agents，2014，43（4）：349-352.
AKAJAGBOR D S，WILSON S L，SHERE-WOLFE K D，et al. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center[J]. Clin Infect Dis，2013，57（9）：1300-1303.
MANCHANDANI P，ZHOU J，BABIC J T，et al. Role of renal drug exposure in polymyxin B-induced nephrotoxi-city[J]. Antimicrob Agents Chemother，2017，61（4）：e02391-e02316.
0
Views
3
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.